Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Current treatment landscape for relapsed MCL

Jonathon Cohen • 4 Sep 2020
SOHO 2020
Lymphoma Mantle Cell Lymphoma CAR-T Ibrutinib Lenalidomide Venetoclax

Jonathon B. Cohen, MD, MS, Winship Cancer Institute of Emory University, Atlanta, GA, provides an overview of the current treatment landscape for relapsed mantle-cell lymphoma (MCL) including the use of BTK inhibitors which are effective in relapsed patients but do not induce long-term remission. Dr Cohen also discusses the use of lenalidomide and venetoclax in this indication, as well as CAR T-cell therapies approved for relapsed MCL. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jonathon Cohen

0:57
Immunotherapeutic approaches for MCL patients who progress following BTKi treatment
Jonathon Cohen • 11 Dec 2023
0:49
Outcomes of patients with MCL who require urgent treatment at time of diagnosis
Jonathon Cohen • 11 Dec 2023
0:55
A pooled analysis to determine the optimal Ki-67 index cut-off point for predicting outcomes in MCL
Jonathon Cohen • 11 Dec 2023
0:55
Updated results of the BRUIN trial: pirtobrutinib in R/R MCL
Jonathon Cohen • 11 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals